Systematic treatment in gastric cancer patients with overt bleeding: A propensity score matching analysis

doi:10.5306/wjco.v15.i9.1177

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1469)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-5) series.

Item

Count

PDF

HTML

746

Figures (1-2)

194

Tables (1-5)

189

Sum=1174

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

208

Sum=249

Sep 24, 2024 (publication date) through Feb 21, 2025

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Clin Oncol. Sep 24, 2024; 15(9): 1177-1187
Published online Sep 24, 2024. doi: 10.5306/wjco.v15.i9.1177

Table 1 Baseline characteristics of patients before propensity score matching, n (%)

Variables	Patients with OBBT (n = 41)	Patients without OBBT (n = 130)	P value	SMD
Gender
Male	30 (73.2)	94 (72.3)	0.914	0.019
Female	11 (26.8)	36 (27.7)
Age (range, years)	65 (47-85)	64 (29-83)	0.003	0.486
BMI (range, kg/m²)	21.0 (15.2-27.2)	22.0 (16.0-33.6)	0.153	0.259
Weight loss (range, %)	8.3 (0-37.4)	5.7 (0-26.0)	0.044	0.399
Smoking history
Yes	15 (36.6)	60 (46.2)	0.282	0.195
No	26 (63.4)	70 (53.8)
Drinking history
Yes	7 (17.1)	17 (13.1)	0.521	0.112
No	34 (82.9)	113 (86.9)
¹Chronic disease
Yes	16 (39.0)	42 (32.3)	0.428	0.141
No	25 (61.0)	88 (67.7)
ECOG-PS
0	1 (2.5)	5 (3.8)	0.010	0.473
1	32 (78.0)	119 (91.5)
2	8 (19.5)	6 (4.6)
Primary tumor location
Body	15 (36.6)	74 (56.9)	0.061	0.429
Pylorus	13 (31.7)	24 (18.5)
Cardia	13 (31.7)	32 (24.6)
Cancer stage (AJCC 8^th)
Stage III	9 (22.0)	33 (25.4)	0.656	0.081
Stage IV	32 (78.0)	97 (74.6)

¹Consisting of hypertension, coronary heart disease, cerebral infarction, diabetes, chronic renal failure, and chronic liver disease.

OBBT: Overt bleeding before treatment; SMD: Standard mean difference; BMI: Body mass index; ECOG-PS: Eastern Corporative Oncology Group Performance Status; AJCC: American Joint Committee on Cancer.

Table 2 Baseline characteristics of patients after propensity score matching, n (%)

Variables	Patients with OBBT (n = 32)	Patients without OBBT (n = 61)	P value	SMD
Gender
Male	23 (71.9)	39 (63.9)	0.440	0.171
Female	9 (28.1)	22 (36.1)
Age (range, years)	64.5 (47-80)	67 (29-81)	0.629	0.100
BMI (range, kg/m²)	22.8 (15.9-27.2)	21.8 (16.0-28.1)	0.757	0.066
Weight loss (range, %)	7.5 (0-33.3)	6.5 (0-23.80)	0.671	0.092
Smoking history
Yes	12 (37.5)	22 (36.1)	0.891	0.030
No	20 (62.5)	39 (63.9)
Drinking history
Yes	5 (15.6)	8 (13.1)	0.986	0.072
No	27 (84.4)	53 (86.9)
¹Chronic disease
Yes	13 (40.6)	25 (41.0)	0.973	0.007
No	19 (59.4)	36 (59.0)
ECOG-PS
0	1 (3.1)	2 (3.3)	0.943	0.076
1	29 (90.6)	54 (88.5)
2	2 (6.3)	5 (8.2)
Primary tumor location
Body	12 (37.5)	26 (42.6)	0.891	0.105
Pylorus	9 (28.1)	16 (26.2)
Cardia	11 (34.4)	19 (31.1)
Cancer stage (AJCC 8^th)
Stage III	6 (18.8)	13 (21.3)	0.771	0.064
Stage IV	26 (81.2)	48 (78.7)

¹Consisting of hypertension, coronary heart disease, cerebral infarction, diabetes, chronic renal failure, and chronic liver disease.

OBBT: Overt bleeding before treatment; SMD: Standard mean difference; BMI: Body mass index; ECOG-PS: Eastern Corporative Oncology Group Performance Status; AJCC: American Joint Committee on Cancer.

Table 3 Therapeutic regimen and best response in patients after propensity score matching, n (%)

Characteristics	Total (n = 93)	Patients with OBBT (n = 32)	Patients without OBBT (n = 61)	P value
Therapeutic regimen
Chemotriplet regimen	36 (38.7)	6 (18.8)	30 (49.2)	0.006
¹Chemodoublet-based regimen	54 (58.1)	24 (75.0)	30 (49.2)
²Monotherapy	3 (3.2)	2 (6.3)	1 (1.6)
Radiographic best response
CR or PR	21 (22.6)	11 (34.4)	10 (16.4)	0.157
SD/no CR or no PR	62 (66.7)	18 (56.2)	44 (72.1)
PD	7 (7.5)	3 (9.4)	4 (6.6)
NA	3 (3.2)	0	3 (4.9)
Radical surgery after systematic treatment
Yes	14 (15.1)	5 (15.6)	9 (14.8)	0.911
No	79 (84.9)	27 (84.4)	52 (85.2)

¹Regimen included a chemodoublet regimen, a chemodoublet plus targeted therapy regimen, and a chemodoublet plus immune checkpoints inhibitor regimen.

²Fluorouracil monotherapy or immune check points inhibitor monotherapy.

OBBT: Overt bleeding before treatment; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; NA: Not available.

Table 4 Treatment-related adverse events (≥ 5%) in patients after propensity score matching, n (%)

	Patients with OBBT (n = 32)		Patients without OBBT (n = 61)
	Any grade	Grade ≥ 3	Any grade	Grade ≥ 3
Any TRAEs	32 (100)	13 (40.6)	55 (90.2)	23 (37.7)
Leukopenia/Neutropenia	23 (71.9)	5 (15.6)	39 (64.0)	13 (21.3)
Constipation	18 (56.3)	0	33 (54.1)	0
Peripheral sensory neuropathy	17 (53.1)	1 (3.1)	30 (49.2)	3 (4.9)
Fatigue	16 (50.0)	0	30 (49.2)	0
Decreased appetite	14 (43.8)	1 (3.1)	29 (47.5)	0
Thrombocytopenia	13 (40.6)	6 (18.8)	16 (26.2)	2 (3.3)
Nausea	12 (37.5)	1 (3.1)	27 (44.3)	4 (6.5)
Vomiting	4 (12.5)	2 (6.3)	13 (21.3)	4 (6.5)
Diarrhea	4 (12.5)	2 (6.3)	14 (23.0)	5 (8.2)
Infection	3 (9.4)	0	5 (8.2)	0
Oral mucosal ulcer	2 (6.3)	0	6 (9.8)	2 (3.3)
Febrile neutropenia	1 (3.1)	1 (3.1)	6 (9.8)	6 (9.8)
Liver injury	1 (3.1)	0	4 (6.5)	1 (1.6)

OBBT: Overt bleeding before treatment; TRAEs: Treatment-related adverse events.

Table 5 Analysis of factors related to overt bleeding after treatment, n (%)

Characteristics	χ² test			Binary logistic analysis
Characteristics	Patients with OBAT (n = 16)	Patients without OBAT (n = 77)	P value	OR (95%CI)	P value
Gender
Male	12 (75.0)	50 (64.9)	0.565
Female	4 (25.0)	27 (35.1)
Age (year)
< 65	7 (43.8)	35 (45.5)	0.901
≥ 65	9 (56.3)	42 (54.5)
Smoking history
No	12 (75.0)	47 (61.0)	0.396
Yes	4 (25.0)	30 (39.0)
Drinking history
No	12 (75.0)	68 (88.3)	0.228	Reference
Yes	4 (25.0)	9 (11.7)		8.512 (1.279-56.655)	0.027
¹Chronic disease
No	7 (43.8)	48 (62.3)	0.169	Reference
Yes	9 (56.3)	29 (37.7)		3.929 (0.974-15.855)	0.055
ECOG-PS
0 or 1	14 (87.5)	72 (93.5)	0.346
2	2 (12.5)	5 (6.5)
BMI (kg/m²)
≤ 18.4	2 (12.5)	9 (11.7)	0.668
18.5-23.9	8 (50.0)	47 (61.0)
≥ 24.0	6 (37.5)	21 (27.3)
Weight loss
< 5%	8 (50.0)	31 (40.3)	0.472
≥ 5%	8 (50.0)	46 (59.7)
Primary tumor location
Pylorus	2 (12.5)	23 (29.9)	0.168	Reference
Body	10 (62.5)	28 (36.4)		10.104 (1.287-79.302)	0.028
Cardia	4 (25.0)	26 (33.8)		1.773 (0.209-15.072)	0.600
Cancer stage (AJCC 8^th)
Stage III	4 (25.0)	15 (19.5)	0.734
Stage IV	12 (75.0)	62 (80.5)
OBBT status
No	6 (37.5)	55 (71.4)	0.009	Reference
Yes	10 (62.5)	22 (28.6)		7.015 (1.726-28.505)	0.006
Therapeutic regimen
Chemotriplet regimen	5 (31.3)	31 (40.3)	0.761
²Chemodouble- based regimen	11 (68.8)	43 (55.8)
³Monotherapy	0	3 (3.9)
Grade 3/4 TRAEs
No	10 (62.5)	47 (61.0)	0.913
Yes	6 (37.5)	30 (39.0)
Radiographic best response
CR or PR	2 (12.5)	19 (24.7)	0.149	Reference
SD/no CR or no PR	10 (62.5)	52 (67.5)		2.763 (0.462-16.504)	0.265
PD	3 (18.8)	4 (5.2)		14.039 (1.158-170.260)	0.038
NA	1 (6.3)	2 (2.6)		32.043 (1.248-822.685)	0.038

¹Consisting of hypertension, coronary heart disease, cerebral infarction, diabetes, chronic renal failure, and chronic liver disease.

²Regimen included a chemo-doublet regimen, a chemo-doublet plus targeted therapy regimen, and a chemo-doublet plus immune checkpoints inhibitor regimen.

³Fluorouracil monotherapy or immune checkpoints inhibitor monotherapy.

OBAT: Overt bleeding after treatment; OR: Odds ratio; CI: Confidence interval; ECOG-PS: Eastern Corporative Oncology Group Performance Status; BMI: Body mass index; OBBT: Overt bleeding before treatment; TRAEs: Treatment-related adverse events; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; NA: Not available.

Citation: Yao YH, Zhang H, Xiao Y, Liu ZT, Shi YY, Yu JY, Li Q, Cao BS. Systematic treatment in gastric cancer patients with overt bleeding: A propensity score matching analysis. World J Clin Oncol 2024; 15(9): 1177-1187
URL: https://www.wjgnet.com/2218-4333/full/v15/i9/1177.htm
DOI: https://dx.doi.org/10.5306/wjco.v15.i9.1177